eighteen
case
acut
eosinophil
pneumonia
identifi
among
us
militari
personnel
deploy
near
iraq
period
incid
case
per
personyear
patient
male
rang
age
year
median
age
year
region
durat
day
month
major
patient
present
breathless
fever
cough
fatigu
pulmonari
infiltr
either
alveolar
alveolar
interstiti
bilater
patient
unilater
rest
median
peak
peripher
eosinophil
count
cellsmm
proport
cell
bronchoalveolar
lavag
fluid
sampl
patient
underw
procedur
eosinophil
rang
twelv
patient
requir
mechan
ventil
patient
die
patient
receiv
antibacteri
agent
patient
given
corticosteroid
clinic
improv
occur
within
h
administr
corticosteroid
radiograph
improv
delay
patient
reevalu
median
month
normal
chest
radiograph
find
report
dyspnea
report
wheez
spirometri
normal
patient
patient
residu
breathless
mildli
reduc
carbon
monoxid
diffus
capac
extens
laboratori
test
fail
yield
evid
specif
etiolog
epidemiolog
investig
found
among
factor
evalu
tobacco
smoke
exposur
report
frequent
among
case
patient
control
subject
vs
furthermor
case
patient
like
recent
start
smoke
case
patient
new
smoker
compar
control
subject
ci
analysi
p
tobacco
product
obtain
theater
fail
reveal
suspect
compon
esper
f
shapiro
ed
weibel
c
et
al
associ
novel
human
coronaviru
kawasaki
diseas
j
infect
di
new
connecticut
esper
colleagu
identifi
novel
coronaviru
associ
human
respiratori
infect
viru
call
hcovnh
human
coronavirusnew
appear
ident
independ
identifi
laboratori
netherland
cours
evalu
respiratori
tract
specimen
recov
children
respiratori
symptom
found
one
coronavirusposit
sampl
obtain
child
kawasaki
diseas
well
previou
detect
unidentifi
antigen
tissu
macrophag
children
kawasaki
diseas
led
investig
explor
possibl
associ
novel
coronaviru
kawasaki
diseas
store
respiratori
specimen
test
viru
use
rtpcr
target
replicas
gene
spike
gene
viru
specimen
avail
children
kawasaki
diseas
seen
period
eight
children
kawasaki
diseas
match
control
subject
evid
coronaviru
infect
esper
colleagu
well
author
accompani
editori
point
number
microorgan
report
associ
kawasaki
diseas
none
associ
confirm
thu
despit
strong
correl
coronaviru
kawasaki
diseas
observ
casecontrol
studi
accept
pathogen
role
must
await
confirm
multin
trial
patient
chronic
hepat
b
hbeag
posit
random
receiv
treatment
either
pegyl
alon
togeth
lamivudin
mg
daili
week
initi
administ
dosag
mg
weekli
decreas
mg
weekli
begin
week
modifi
intentiontotreat
analysi
combin
therapi
associ
frequent
endoftreat
clearanc
hbeag
monotherapi
vs
p
p
subsequ
relaps
elimin
advantag
thu
week
end
treatment
patient
assign
receiv
monotherapi
assign
receiv
combin
therapi
hbeag
neg
patient
infect
genotyp
b
better
outcom
infect
genotyp
c
similar
result
obtain
suppress
viral
dna
serum
alanin
aminotransferas
concentr
analyz
lead
conclus
pegyl
effect
treatment
hbeagposit
chronic
hepat
b
viru
infect
addit
lamivudin
treatment
regimen
provid
addit
benefit
avail
lamivudin
adefovir
made
treatment
chronic
hepat
b
toler
patient
ifna
howev
associ
durabl
treatment
respons
although
recommend
unit
state
remain
equivoc
european
guidelin
current
recommend
ifna
initi
therapeut
choic
treatmentna
patient
chronic
hepat
b
viru
infect
sinc
recommend
made
pegyl
ifna
demonstr
superior
nonpegyl
product
treatment
infect
marcellin
et
al
recent
report
pegyl
monotherapi
superior
lamivudin
monotherapi
administr
drug
combin
patient
hbeagneg
chronic
hepat
b
janssen
colleagu
demonstr
week
combin
therapi
lamivudin
ad
rel
low
dose
pegyl
superior
therapi
alon
patient
hbeagposit
chronic
hepat
b
viru
infect
vertebr
defens
microbi
pathogen
gener
consid
consist
aspect
innat
adapt
immun
innat
respons
involv
recognit
pathogenassoci
molecular
pattern
cell
surfac
receptor
rel
broad
specif
result
signal
trigger
mobil
antimicrobi
effector
innat
respons
independ
immunolog
memori
adapt
immun
respons
contrast
depend
epitop
bind
specif
receptor
innat
respons
effect
even
immunolog
naiv
host
wherea
adapt
respons
depend
degre
immunolog
educ
requir
minimum
sever
day
becom
activ
innat
immun
respons
viral
pathogen
requir
secondari
intracellular
event
ifn
product
consequ
appear
delay
hour
bienasz
propos
third
aspect
host
respons
viral
pathogensintrins
immunitywhich
act
immedi
viruscel
interact
two
promin
exampl
effector
intrins
immun
tripartit
interact
motif
apolipoprotein
edit
complex
activ
certain
retrovirus
includ
restrict
factor
may
account
resist
nonhuman
primat
infect
human
retroviru
bind
incom
retrovir
capsid
although
activ
retrovirus
human
unfortun
potent
inhibitor
second
exampl
effector
intrins
immun
host
incorpor
viral
particl
deamin
cytidin
uracil
ultim
result
gtoa
mutat
result
lethal
retrovir
hypermut
sequenc
event
howev
prevent
vif
protein
bind
concept
intrins
immun
use
allow
one
better
understand
antivir
defens
mechan
cleanli
fit
previous
exist
categori
